Baseline DPP-IV Not Found to Predict Incident Diabetes
DPP-IV similar in those who do and don't develop diabetes; highest quartile doesn't have higher risk
FRIDAY, May 28 (HealthDay News) -- Fasting levels of dipeptidyl peptidase IV (DPP-IV) don't appear to predict later diabetes, according to research published in the May issue of Diabetes Care.
Vivian C. Luft, of the Federal University of Rio Grande do Sul in Porto Alegre, Brazil, and colleagues analyzed data from a case-cohort sample drawn from the Atherosclerosis Risk in Communities study that involved middle-aged and older individuals who were followed for nine years. They analyzed DPP-IV levels from samples collected at baseline from 546 subjects who developed diabetes and 538 who did not.
The researchers found that DPP-IV levels had minimal correlation with inflammatory, metabolic, or body-measurement variables. In addition, mean DPP-IV values were similar in those who did and did not develop diabetes (P = 0.18). Subjects in the highest quartile of DPP-IV didn't have a higher risk of diabetes after adjustment for age, race, and other diabetes risk factors.
"Despite the fact that DPP-IV, the major inhibitor of incretins, has proinflammatory actions, fasting DPP-IV levels do not appear to predict the development of diabetes. Fasting DPP-IV is thus unlikely to be a link between inflammation and the development of diabetes. African Americans present adjusted DPP-IV mean values approximately 10 percent higher than their white counterparts," the authors conclude.